Overview
Plain-language guide
A product-specific treatment to help control excess red blood cell production in adults with polycythemia vera.
It copies an iron-regulating hormone, reducing the iron available for making red blood cells.
Clinical mechanism
Mimics hepcidin to limit iron availability for red-blood-cell production.
Applications
Human evidence
Multiple human studies and regulatory review support at least one product-specific indication.
Tier 1Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Approved. United States: Mimrylo for erythrocytosis in adults with polycythemia vera.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Follow the current Mimrylo prescribing information. Its preparation and short post-mixing use window are not represented by a generic multidose-vial tracker.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Takeda / Protagonist Therapeutics · FDA approved. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
2026-08-28: FDA approval of a hepcidin-mimicking treatment for polycythemia vera.
- 01FDA: Mimrylo approval announcement ↗
Regulator · 2026-08-28
- 02FDA: Mimrylo prescribing information ↗
Regulator · 2026-08-28
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
September 23, 2026 (listed facts only) · Primary-source check needed